Baird Medical Investment Holdings Ltd. develops and commercializes minimally invasive microwave ablation (MWA) medical devices, with a focus on thyroid-related diseases and other soft tissue conditions. News about BDMD commonly covers sales of MWA needles and microwave therapeutic apparatuses, distributor and direct-customer activity, clinical education for physicians, and the company's geographic expansion beyond Mainland China.
Updates also include regulatory clearances in international markets, U.S. clinical-conference engagement, and product-development work tied to software, AI-assisted planning, and robotic surgical systems. Financial releases discuss revenue mix, gross margin, R&D spending, and the effects of market policy and pricing dynamics on the company's China business.
Baird Medical Investment Holdings (NASDAQ: BDMD) announced that Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, has completed 100 Microwave Ablation (MWA) procedures for thyroid nodules. This milestone demonstrates the increasing adoption of MWA technology in thyroid treatment.
Dr. Kandil's achievement highlights MWA as a safe and effective alternative to traditional thyroid surgery, offering benefits such as faster recovery times, reduced procedural risks, and improved quality of life. Baird Medical presented Dr. Kandil with a Certificate of Excellence for his contributions to advancing thyroid care.
The company reaffirmed its commitment to advancing MWA technology through continued collaboration with physicians and investment in medical education.
Baird Medical (NASDAQ: BDMD), a leader in minimally invasive Microwave Ablation (MWA) technology, participated in activities surrounding the 2025 J.P. Morgan Healthcare Conference in San Francisco. Following its Nasdaq debut in October 2024, the company engaged with healthcare investors and industry leaders, discussing advancements in microwave ablation technology and patient outcomes.
Chairwoman Haimei Wu highlighted the conference's importance in connecting with shareholders, innovators, and healthcare sector advisors. The company plans to utilize these interactions to support its 2025 strategic initiatives, focusing on expanding its U.S. presence and strengthening collaborations with key opinion leaders (KOLs) in medical technology.
Baird Medical (NASDAQ: BDMD) recently sponsored an advanced Microwave Ablation (MWA) training session in New Orleans, focusing on thyroid nodule treatment. The program was led by Dr. Emad Kandil from Tulane University School of Medicine, with participation from Dr. Sean P. Nikravan and Dr. Erin H. Lin.
Participants observed seven live MWA procedures, gaining hands-on experience in precision targeting and workflow optimization. The training emphasized the technology's efficiency and potential for improved patient outcomes, including faster recovery times. Following the session, the physicians engaged in clinical discussions and received Certificates of Completion.
Chairwoman Haimei Wu emphasized the importance of hands-on training and expert collaboration in advancing MWA technology adoption for thyroid treatments.
Baird Medical (NASDAQ: BDMD), a leader in minimally invasive microwave ablation (MWA) technology, sponsored and participated in the 4th Sichuan Medical Association Thyroid Disease Academic Conference in China. The company showcased its advanced MWA technology for thyroid nodules, featuring larger ablation zones and shorter treatment times.
During the conference, which brought together prominent thyroid specialists and healthcare professionals, Baird Medical engaged in discussions with medical leaders and presented its innovative solutions. Chairwoman Haimei Wu emphasized the company's commitment to advancing thyroid disease treatment and improving patient outcomes through technological innovation and professional collaboration.
Baird Medical (NASDAQ: BDMD) participated in and supported the 2024 Guangdong Provincial Parathyroid Disease - Southern Yue Forum in Guangzhou, China. The company, specializing in minimally invasive microwave ablation (MWA) technology, showcased its innovations in endocrine care at the event.
The forum brought together medical experts, researchers, and healthcare professionals to discuss advancements in parathyroid disease diagnosis and treatment. As a sponsor, Baird Medical presented its MWA technology designed for endocrine conditions, engaging with key opinion leaders and fostering collaborations to better understand clinical needs.
Baird Medical (NASDAQ: BDMD) sponsored an advanced Microwave Ablation (MWA) training session in New Orleans, focusing on thyroid treatment. The session was led by Dr. Emad Kandil from Tulane University School of Medicine, with participation from Dr. Salem Noureldine of George Washington University. Dr. Noureldine observed five live MWA cases and practiced advanced techniques.
Dr. Kandil, who has performed over 80 MWA procedures, recently presented at the American Thyroid Association meeting, highlighting MWA's effectiveness compared to Radiofrequency Ablation. The training emphasized MWA's efficiency and patient-centered design, notably the absence of grounding pads. Dr. Noureldine received a Certificate of Completion, preparing him to integrate MWA into clinical practice.
Baird Medical (NASDAQ: BDMD) sponsored and participated in the 2024 Guangdong Thyroid Surgery Committee Annual Meeting in Guangdong, China. The two-day event, hosted by the Guangdong Provincial Hospital of Traditional Chinese Medicine, focused on advancing thyroid disease treatment. Baird Medical showcased its microwave ablation (MWA) technology and engaged with healthcare professionals to discuss innovations in endoscopic and minimally invasive surgery.
Chairwoman Haimei Wu emphasized the meeting's importance as a platform for sharing advancements in thyroid ablation and fostering collaboration among experts. The company utilized the interactive sessions to engage with specialists about current challenges and future directions in thyroid care, reinforcing its commitment to advancing minimally invasive surgery solutions globally.
Baird Medical (NASDAQ: BDMD) recently sponsored an advanced Microwave Ablation (MWA) training session in New Orleans, focusing on thyroid care advancement. Led by Dr. Emad Kandil from Tulane University School of Medicine, the program provided hands-on training to two endocrinologists who observed seven live MWA cases.
Dr. Kandil, who has performed over 80 MWA procedures, recently presented at the American Thyroid Association meeting, highlighting MWA's effectiveness compared to Radiofrequency Ablation. The participating physicians received Certificates of Completion, preparing them to integrate MWA into their clinical practices.
The initiative reflects Baird Medical's commitment to expanding access to minimally invasive therapies through physician education and training partnerships.
Baird Medical Group (NASDAQ: BDMD) held its 2024 Annual Review and 2025 Planning Meeting at Baird Capital Tower in Guangzhou, China. The two-day event included participation in the 7th Thyroid Disease Forum and comprehensive reviews of market performance and future strategies.
Production Manager Le Zhang presented the 2025 production schedule and plans for enhanced after-sales service. The company's leadership discussed strengthening distributor relationships to support global expansion goals. The meeting highlighted Baird Medical's recent NASDAQ listing as a milestone that increased international recognition in the minimally invasive medical technologies sector.
Baird Medical (NASDAQ: BDMD) sponsored and participated in the 2024 7th Thyroid Disease Standardized Diagnosis and Treatment Forum in Guangzhou, China. The company showcased its advanced microwave ablation (MWA) technology for thyroid treatments, which features larger ablation zones and shorter treatment times. The event, hosted by Guangdong Provincial People's Hospital, brought together leading medical experts to discuss standardized treatment protocols for thyroid diseases. Chairwoman Haimei Wu emphasized the company's commitment to advancing solutions for thyroid disease management and improving patient outcomes globally.